The Cancer Microenvironment research program leverages expertise in cancer immunology, niche biology, radiation effects, and novel bioengineering tools to understand mechanistically and manipulate immune and mesenchymal cell populations that regulate normal stem cells but are hijacked to support cancer stem cells.
Wilmot research teams are focused on benign and malignant stem cells and radiation biology in cancers that are heavily impacted by their tumor microenvironment and toxic exposures, such as breast, gastrointestinal, bladder, melanoma, and lymphoma and leukemia.
The program has three specific aims:
- Reprogram tumor-induced signals that silence normal cancer immunity.
- Disrupt supportive microenvironments for cancer cells.
- Mitigate dysfunction of normal tissue induced by cancer treatment.
Laura Calvi, M.D., professor of Medicine, Neurosurgery, and Pharmacology and Physiology
Dr. Calvi is focused on bridging bone and stem cell biology to discover the regulatory components of the bone marrow microenvironment, to identify targeted therapies.
Minsoo Kim, Ph.D., Dean’s Professor of Microbiology and Immunology and director of the Tumor Immunotherapy Research Program at Wilmot
Dr. Kim investigates innate and adaptive immune responses and cancer treatment.